Haoxi Health Technology Limited Announces 1-for-25 Reverse Share Split
24 January 2025 - 12:30AM
Haoxi Health Technology Limited (the “Company” or “HAO”), an online
marketing solution provider headquartered in Beijing, China, today
announced that it has resolved to effect a reverse share split of
the Company’s ordinary shares, with the split ratio set at 1-for-25
(the “Reverse Share Split”). The Reverse Share Split was approved
by the Company’s shareholders at an annual general meeting of
shareholders held on January 10, 2025. The Company’s Class A
ordinary shares will begin trading on an adjusted basis on the
Nasdaq Capital Market, reflecting the Reverse Share Split, when the
market opens on January 27, 2025, under the existing ticker
symbol “HAO.” The new CUSIP number for the Company’s Class A
ordinary shares will be G4290F118.
Upon the effectiveness of the Reverse Share
Split, every twenty-five shares of the Company’s issued and
outstanding Class A ordinary shares as of the effective date will
automatically be combined into one Class A ordinary share, and
every twenty-five shares of the Company’s issued and outstanding
Class B ordinary shares as of the effective date will automatically
be combined into one Class B ordinary share. This adjustment will
reduce the total number of outstanding Class A ordinary shares of
the Company from approximately 53.29 million to approximately 2.13
million, and the total number of outstanding Class B ordinary
shares of the Company from approximately 17.27 million to
approximately 0.69 million.
In conjunction with the Reverse Share Split, the
Company also amended its Articles and Memorandum of Association to
proportionately reduce the number of authorized shares for issuance
and to adjust the par value of the post-reverse share split
ordinary shares to $0.0025 per share.
No fractional shares will be issued; instead,
shareholders who would otherwise be entitled to a fractional share
will have their entitlement rounded up to the nearest whole
share.
The Reverse Split is expected to lead the
Company’s Class A ordinary shares to trade at approximately
twenty-five times the price per share at which it trades prior to
the effectiveness of the Reverse Split. The Company, however,
cannot assure that the price of its Class A ordinary shares after
the Reverse Split will reflect the 1 for 25 Reverse Split ratio,
that the price per share following the effective time of the
Reverse Split will be maintained for any period of time, or that
the price will remain above the pre-split trading price.
Further details regarding the reverse share
split and the associated changes to the Company’s share capital can
be found in the Company’s notice of 2025 annual general meeting,
filed with the Securities and Exchange
Commission on December 19, 2024.
About Haoxi Health Technology Limited
Haoxi Health Technology Limited is an online
marketing solution provider headquartered in Beijing, China,
specializing in serving healthcare industry advertiser clients. The
Company’s growth is driven by the rise of news feed ads and the
rapid development of the healthcare sector. The Company offers
one-stop online marketing solutions, especially in online short
video marketing, helping advertisers acquire and retain customers
on popular platforms in China, such as Toutiao, Douyin, WeChat, and
Sina Weibo. The Company is dedicated to reducing costs, increasing
efficiency, and providing easy online marketing solutions to
advertisers. For more information, please visit:
http://ir.haoximedia.com.
Forward-Looking Statement
This press release contains forward-looking
statements as defined by the Private Securities Litigation Reform
Act of 1995. Forward-looking statements include statements
concerning plans, objectives, goals, strategies, future events or
performance, underlying assumptions, and other statements that are
other than statements of historical facts. When the Company uses
words such as "may, "will, "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's goals and strategies; the Company's
forecast on market trends; the Company's future business
development; the demand for and market acceptance for new services;
expectation to receive customer orders for new services; the
anticipated timing for the marketing and sales of new solutions;
changes in technology; the Company's ability to attract and retain
skilled professionals; client concentration; and general economic
conditions affecting the Company's industry and assumptions
underlying or related to any of the foregoing and other risks
contained in reports filed by the Company with the SEC. For these
reasons, among others, investors are cautioned not to place undue
reliance upon any forward-looking statements in this press release.
Additional factors are discussed in the Company's filings with the
SEC, which are available for review at www.sec.gov. The
Company undertakes no obligation to publicly revise these
forward-looking statements to reflect events or circumstances that
arise after the date hereof.
For more information, please contact:
Investor Relations
WFS Investor Relations Inc.
Janice Wang, Managing Partner
Email: services@wealthfsllc.com
Phone: +86 13811768599
+1 628 283 9214
Haoxi Health Technology (NASDAQ:HAO)
Historical Stock Chart
From Dec 2024 to Jan 2025
Haoxi Health Technology (NASDAQ:HAO)
Historical Stock Chart
From Jan 2024 to Jan 2025